Peer-reviewed veterinary case report
Treatment results and outlook for cats with immune thrombocytopenia
By Zhong, Mulan et al.·Published in Journal of veterinary internal medicine·2026·Sydney School of Veterinary Science, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Treatment outcomes and prognostic indicators of primary immune thrombocytopenia in 31 cats: a multicenter retrospective study (2000-2023).
- Species:
- cat
Plain-English summary
A group of 31 cats diagnosed with primary immune thrombocytopenia (ITP), a rare condition that affects blood platelets, were treated with immunosuppressive medications to see how well they responded. Most of the cats (87%) survived their hospital stay, and 81% achieved a safe platelet count, but only about a third went into remission. Cats treated with a combination of corticosteroids and cyclosporine had longer hospital stays compared to those on corticosteroids alone. Overall, while the short-term outlook for these cats is fair, many experienced relapses, highlighting the need for careful follow-up care.
People also search for: cat immune thrombocytopenia treatment · cat low platelet count symptoms · cat ITP prognosis
Abstract
BACKGROUND: Primary immune thrombocytopenia (ITP) in cats is rare. Evidence is lacking on effective immunosuppressive protocols, prognosis, and prognostic indicators. HYPOTHESIS/OBJECTIVES: To investigate immunosuppressive treatment outcomes and prognostic indicators of cats with primary ITP. ANIMALS: Thirty-one cats with primary ITP. METHODS: Multi-institutional retrospective cohort study (2000-2023). Cats were identified by searching medical records from 12 institutions. Immunosuppressive treatments and prognostic indicators were studied in association with clinical outcomes. Indicators included age, sex, breed, bodyweight, initial platelet count and PCV, blood urea nitrogen concentration, and blood product administration. Outcomes including medical control (platelet count > 57 000/μL), relapse, remission, death, and survival to discharge were analyzed using logistic regression models. Hospitalization duration, days to medical control, remission, and death were assessed using linear regression models. Survival was assessed using the Kaplan-Meier method. RESULTS: Of the cats included, 27/31 (87%) survived to discharge, 25/31 (81%) achieved medical control, 8/25 (32%) achieved remission, 10/25 (40%) relapsed during immunosuppressive tapering, and 5/10 (50%) had a second relapse. Cats administered corticosteroids and cyclosporine had longer hospitalizations than corticosteroids alone (8.4 ± 0.9 vs 4.4 ± 0.9 days; P = .005). Median survival was not reached. Median follow-up was 315 days (95% CI, 216-1252). CONCLUSIONS AND CLINICAL IMPORTANCE: Cats with primary ITP have a fair short-term prognosis and low remission rate. The frequent relapse rate warrants close monitoring. Besides longer hospitalization durations, combination immunosuppressive treatment did not affect other outcomes, when compared to corticosteroids alone.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41742513/